Autolus Therapeutics PLC (AUTL)
6.24
+0.07
(+1.13%)
USD |
NASDAQ |
Mar 27, 16:00
6.24
0.00 (0.00%)
After-Hours: 06:21
Autolus Therapeutics Cash from Financing (TTM): -0.883M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.883M |
September 30, 2023 | 222.60M |
June 30, 2023 | 222.70M |
March 31, 2023 | 222.92M |
December 31, 2022 | 223.61M |
September 30, 2022 | 147.52M |
June 30, 2022 | 147.18M |
March 31, 2022 | 160.74M |
December 31, 2021 | 284.06M |
Date | Value |
---|---|
September 30, 2021 | 137.04M |
June 30, 2021 | 137.28M |
March 31, 2021 | 123.43M |
December 31, 2020 | 74.42M |
September 30, 2020 | 74.06M |
June 30, 2020 | 73.47M |
March 31, 2020 | 183.17M |
December 31, 2019 | 108.86M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.883M
Minimum
Dec 2023
284.06M
Maximum
Dec 2021
149.54M
Average
147.18M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Adaptimmune Therapeutics PLC | 0.88M |
NuCana PLC | -0.0659M |
TC BioPharm (Holdings) PLC | 10.56M |
Biodexa Pharmaceuticals Plc | 7.972M |
Mereo BioPharma Group PLC | -1.725M |